bluuebunny/crossref_metadata_2025_split huggingface dataset:
Effect of weekly administration of bevacizumab, eribulin, and oxalilplatin in patients with heavily pretreated serous ovarian carcinoma.
Authors: Ikeda Yuji , Takano Masashi , Sasaki Naoki , Kita Tsunekazu , Kikuchi Yoshihiro , Kudoh Kazuya 
Published: March 2020

e16506 Background: Eribulin, inhibiting a protein component of tubulin, extend the lifespan of patients with late-stage breast cancer who are not benefiting paclitaxel. Bevacizumab (B) is known to enhance chemotherapeutic efficacy of platinum agents. We evaluated the effect of weekly administration of B with eribulin and oxaliplatin (EriOX) in recurrent or refractory serous ovarian carcinoma patients (ROC) pretreated with paclitaxel and carboplatin. Methods: Thirteen patients with ROC had treated with weekly-B and EriOX consisting of B (2mg/kg), eribulin (1mg/m2) and oxaliplatin (30mg/m2). The response and adverse effects (AE) were evaluated using the response evaluation criteria in solid tumors (RECIST), CA125 Gynecologic Cancer Intergroup (GCIG) criteria, and common terminology criteria for adverse events (CTCAE) version 4.0. Results: One patient is still under treatment of two cycles. We evaluated 12 patients at least two or more cycles of weekly B and EriOX. Ten patients (83%) were primarily stage 3 or 4. Ten patients (83%) had received three or more regimens of chemotherapy. All patients were pretreated with paclitaxel and carboplatin and 9 patients (75%) had been pretreated with platinum containing regimen within 6 months. According to the RECIST evaluation, 2 patients (17%) had a complete response (CR), 1 patient (8%) had a partial remission (PR) and 3 patients (25%) had a stable disease (SD). The response rate (CR+PR) and clinical benefit rate (CR+PR+SD) were 25% and 50%, respectively. Median progression-free survival was 3 months (range: 1-5 months). Hematological AEs with grade 3/4 were observed in 2 patients (17%). Hypo albuminemia and edema with grade 3 were in 1 patient (8%), respectively. However, all AE were manageable and torelable. Conclusions: Weekly B and EriOX administration had significant activity with mild AE in patients with paclitaxel and platinum resistant ROC. These results warrant further prospective study.
Time to vulva cancer relapses in dependence on different factors.
Authors: Nerodo Galina , Ivanova Victoria Aleksandrovna , Nerodo Ekaterina Alekseevna 
Published: March 2020

e16513 Background: The time to relapses was investigated in dependence on different factors. Methods: We examined 809 vulva cancer patients to evaluate frequency and average time to relapse depending on grades, invasion depth and method of treatment. Results: We found out that 25.09% (203 from 809) of patients had a relapse. For the I grade the relapse was observed in 18.29% patients after 59.3 months on average, for the II grade – in 20.5% after 46.9 months, for the III grade – in 26.6% after 16.8 months, for the IV grade – in 46.2% patients after 7.2 months respectively. The patients of the II grade with tumor invasion of 1-2 mm had a relapse after 61.2 months, with invasion of 3-4 mm – after 42.1, with more than 5 mm – after 38.5 months on average correspondingly. For patients of the III grade with tumor invasion less than 5 mm the average time to relapse was 19.9 months, with invasion more than 5 mm – 12.6 months. There is not significant difference between the times to relapses of early grades patients treated with combined method or complex method with chemotherapy. However for the patients of the III grade the chemotherapy has prolonged the time to relapse from 13.5 to 18.1 months. Conclusions: The relapses of vulva cancer were observed in 25.09% of all patients. The grade, depth of invasion and chemotherapy as a part of complex treatment of III-IV grades patients have considerable influence on the time to relapse.
Structural indices of erythrocytes membrane in patients with vulvar cancer.
Authors: Goroshinskaya Irina Aleksandrovna , Nerodo Galina , Nemashkalova Ludmila Anatolievna , Surikova Ekaterina Igorevna , Nerodo Ekaterina Alekseevna 
Published: March 2020

e16515 Background: The analysis of membranes flow property in the zone of protein and lipid contacts, and of proteins submergence degree into lipid erythrocytes membrane bilayer in patients with vulvar cancer. Methods: 34 patients with vulvar cancer at the different stages of the disease were examined. We studied the characteristics of blood erythrocytes membranes with the use of pyrene probe: flow of protein and lipid contacts zones and lipid bilayer, submergence of proteins into lipid bilayer. Results: The analysis of the data received showed, that the most interesting results were obtained during the study of proteins submergence level. In the group with vulva primary tumor the level of proteins submergence into erythrocytes membrane lipid matrix was authentically higher than 25.9% (0.243±0.012, p < 0.001) as compared with the index the healthy women have (0.193±0.006). The degree of proteins submergence into lipid matrix of the patients, being at the state of remission, was decreasing by 25.1% (0.182±0.013, p < 0.01), as compared with the index in the group with primary tumor, achieving the level of the healthy women. Subsequently, during the progress of the relapse, the proteins submergence increased again (0.242±0.019, p < 0.01), achieving the indices in the group with primary tumor. Also, membrane flow property in the zone of protein and lipid contacts was increasing by 25.1% (0.564±0.053, p < 0.05) in the group with relapse, as compared with the group of the primary tumor (0.451±0.017). Conclusions: According to our observations, the increase of proteins submergence into erythrocytes membrane lipid matrix in patients with vulva cancer in remission preceded the clinical manifestation of the disease’s relapse, thus showing the prognostic significance of blood erythrocytes membranes studying during the progress of vulvar cancer.
Ovarian granulosa cell tumors: Experience of National Institute of Oncology in Morocco.
Authors: Sekkate Sakina , Kairouani Mouna , Serji Badr , el Ghissassi Brahim , Mrabti Hind , Errihani Hassan 
Published: March 2020

e16527 Background: The granulosa cell tumors are malignancies with a relatively favorable prognosis. They are characterized by prolonged natural history and tendency to late recurrences. The aim of this study is to investigate the epidemiological and pathological characteristics of granulosa cell tumors, and the prognosis factor for recurrences in the national institute of oncology in Rabat in Morocco. Methods: The clinical data of patients with adult granulosa cell tumors of the ovary treated from January 2003 to december 2010 was investigated retrospectively. Data of age, clinical manifestation, imaging, diagnosis, treatment and follow up of the patients were reviewed and analyzed. Histology was obtained in postoperative for all patients. Results: Twenty-seven cases were retrieved. The median age was 53 years. The most common clinical manifestations at diagnosis were: abdominal pain, vaginal bleeding, abdominal distension and hormonal manifestations. The mean tumor size was 14 cm. The majority of patients had stage I (62,96%, n = 17), while (18,51%, n = 5) had stage III, (7,4%, n = 2) had stage IV, and (11,11%, n = 3) of patients had unknown stage.8 patients received adjuvant chemotherapy (4 : bleomycin etoposide, cisplatin (BEP); 1: bleomycin vepeside cisplatin (BVP); 1: endoxan cisplatin; 1: paclitaxel cisplatin; 1: tamoxifene), and 2 patients received chemotherapy for metastatic disease.For a median follow up of 63,44 months, 5 (18,51%) of patients relapsed. The median time to relapse was 41,8 months, (range : 18-62 months).The overall 5-year survival and 9-year survival rates for all stages were 91.3% and 77.3%, respectively. Following univariate Cox regression modeling, the survival depends on stage, it’s better in localized stages (p = 0,05). Conclusions: Granulosa cell tumor of the ovary is an uncommon neoplasm. The adult form progresses slowly and often is diagnosed in an early stage of disease. Surgery is indicated. A prolonged post therapeutic follow-up is necessary because of the risk of recurrences, late and exceptional for the adult form.
Bevacizumab-based therapy in patients with heavily pretreated ovarian and other Mullerian tract cancers.
Authors: Kurbacher Jutta Anna , Lepique Jutta , Herz Susanne , Wessling Gabriele , Kurbacher Christian M. 
Published: March 2020

e16533 Background: Bevacizumab (Bev) is approved for the therapy (Tx) of primary and platinum-sensitive recurrent Mullerian tract cancers (MTC) such as ovarian (OC), fallopian tube (FTC), type II endometrial (EC-II), and peritoneal papillary-serous carcinomas (PPSC). However, the role of Bev in the ≥ 3rd line Tx of MTCs is still unclear.This retrospective study summarizes our long-term experiences with Bev in patients (pts) with heavily pretreated MTC who did not qualify for recruitment into a controlled clinical trial. Methods: A total of 74 intensively pretreated MTC pts (OC, n = 65; FTC, n = 2; EC-II, n = 4; PPSC, n = 3) were included in this study with 43 (58.1%) being platinum-resistant. Pts had failed a median of 4 (range 1-10) prior chemotherapies (CTx ). Tx included Bev monotherapy (group A, n = 17), Bev + metronomic CTx (group B, n = 37), and Bev + conventionally dosed CTx (Group C, n=20). Bev was administered at either 10 mg/kg BW q2w or 15 mg/kg BW q3w. Adverse effects were classified according to CTCAE Vs 4.03. TTP was calculated from the start of Bev until progression, OS was calculated from the start of Bev until death or loss to follow up. Results: Most common Tx related toxicities were hypertension, proteinuria, headache, inflammation/infection, epistaxis, and subileus. Hypertension which often required adequate treatment was limiting in only one case as also were renal toxicity and infection. Median TTP was 27.8 wks and median OS was 53.6 wks with no significant difference between platinum-resistant and –sensitive pts. In regard to both TTP and OS, there was a non-significant trend favoring groups A (33.4/63.0 wks) and B (29.9/61.6 wks) vs group C (19.2/35.4 wks). Conclusions: Bev based Tx was active and generally well tolerated in this hard-to-treat population of pts with recurrent MTC. Both TTP and OS were equal or even superior to any conventional CTx used in this setting. Moreover, clinical platinum-resistance did not predict a worse clinical outcome. Although this is not a randomized trial, our results argue in favor that Bev should be preferably given either as single agent or combined with metronomic CTx in pts with heavily pretreated MTCs. Further clinical trials of Bev in recurrent MTCs may prove useful.
Perioperative epidural analgesia and recurrence-free survival for ovarian cancer surgery: A retrospective analysis.
Authors: Koensgen Dominique , Mustea Alexander , Rosanowski Barbara , Leutzow Bianca , Hesse Thomas , Patrzyk Maciej , Heidecke Claus Dieter , Zygmunt Marek , Wendt Michael , Usichenko Taras 
Published: March 2020

e16534 Background: Current experimental and clinical data suggest that perioperative factors may influence the long-term outcome after cancer surgery. Recent retrospective analyses have shown the reduction of cancer recurrence and metastatic spread in patients after tumor surgery receiving perioperative regional and neuraxial analgesia. The aim was to investigate whether perioperative epidural anesthesia is associated with the decreased disease recurrence and increased survival after primary tumor debulking in patients with ovarian cancer. Methods: Retrospective analysis of consecutive patients with primary ovarian cancer who underwent radical multivisceral surgery between 01/2003 and 12/2010 under either general anesthesia plus opioid analgesia (group A) or general anesthesia plus epidural anesthesia (group B), was performed. Cancer recurrence-free survival and total survival times after surgery were compared between the groups using Mann-Whitney test. The analysis was strengthened by Kaplan-Meier survival estimates for each group with comparison using the log-rank test. Results: Data of 105 (88%) of patients (group A: 33; group B: 72) were available for analysis. The median (interquartile range-IQR) follow-up time 27 (17-58) months. The groups were comparable regarding age, body-mass index, ASA physiological status, FIGO staging, tumor residual and use of adjuvant platinum-based chemotherapy. The median (IQR) time to recurrence of cancer was 31 (15-63) months in group A vs. 18 (10-35) months in group B (p = 0.017). Longer recurrence-free survival was associated with general anesthesia and opioid analgesia (hazard ratio 1.52; 95% confidence interval 1.4-1.56; p = 0.008). Conclusions: In contrast to previous investigations, perioperative epidural anesthesia was associated with decreased survival in patients after ovarian cancer surgery.
Correlation of in vitro chemotherapy drug resistance assay to clinical response to carboplatin and paclitaxel combination chemotherapy in ovarian carcinoma.
Authors: Cheng Kit , Shapira Iuliana , Rosen Lisa M , John Veena S. , Lovecchio John L. , Menzin Andrew , Whyte Jill Suzanne , Dos Santos Lisa A. , Contreras Diana , Shih Karin , Roy Rajasree , Lee Annette , Hayes Christi , Ahmad Nazish , Tandon Pragati , Hoffman Mark Allan 
Published: March 2020

e16546 Background: Carboplatin sensitivity in drug resistance assays has been shown to be an independent predictor of longer progression free interval with conflicting results in overall survival. We evaluated in vitro drug resistance for carboplatin and paclitaxel combination and its correlation with progression free survival (PFS) and overall survival (OS). Methods: From April 1, 2006 to December 12, 2011, in vitro drug resistance assays were sent after cytoreductive surgery for primary epithelial ovarian cancer. Patients were analyzed according to drug resistance scoring system of low drug resistance (S), intermediate drug resistance (I), and extreme drug resistance (R). Retrospective chart review was performed to evaluate PFS and OS. The Kaplan Meier product limit method was used to estimate OS and PFS. Survival curves were compared between groups using the log rank test. Results: From a total of 142 patients: 57 were S, 52 I, and 33 R; 77% were responsive (S+I) to carboplatin and paclitaxel combination. At median follow-up of 18 months, PFS and OS rates were 58.1 and 91.3% respectively for S, 66.1 and 78.7% for I, and 43.2% and 84.3% for R. At 36 months, the PFS and OS rates were 52.3 and 61.1% for S, 51.3 and 55.3% for I and 39.3% and 48.7% for R. There was OS advantage between the S and I compared to R. There were no significant differences in PFS curves (p<0.281) or OS curves (p<0.46). Conclusions: Although sensitivity to carboplatin/ paclitaxel resulted in longer OS, the results were not statistically significant. Our cohorts were small and we may not have had the power to capture statistical significance. A larger multicenter analysis would be needed to further evaluate this finding. In addition, one of the regimens our patients received on relapse was bevacizumab which was not evaluated in the in vitro assay sensitivity assay. Bevacizumab has also been included in first line treatment in combination with platinum/ taxane regimen. Future analysis of in vitro assays may need to include biologics.
The chemotaxis study of adipose derived stem cells (ADSCs) to adenoid cystic carcinoma (ACC) cells.
Authors: Hua Li , Zhengxue Han 
Published: March 2020

e17000 Background: Adenoid cystic carcinoma (ACC) has some properties such as neurotropic, angiotropic and early metastasis, recurrence and metastasis is the leading cause of poor prognosis in sACC. The current theory is that the invasion and metastasis were related to tumor stem cells, and the stem cell microenvironment play an important role in this process. According to the stem cell theory, we hypothesized that normal tissue stem cells may also produce chemotactic migration to tumor stem cell microenvironment, therefore this research was to explore the possibility of adipose derived stem cells as a therapy vector targeted to the microenvironment of ACC. Methods: Conventionally culture ACC cells to logarithmic growth phase, then collected them and cultured in serum-free medium. After 48 h, the culture supernatant was collected, filtered and prewarmed, and then added to each well (24-well plate, the lower chamber of the transwell chamber), 600-800 ul for each. Using the same method, the culture supernatant of T293 cells were joined into the lower chamber as a control. Then, the transwell membrane was gently placed into the well, and 100 ~ 150μl suspension of adipose derived stem cells in the logarithmic growth phase (serum-free media) were added into the upper chamber. After cultured under routine conditions for 24 hours, the transwell chamber were removed , fixed and stained. Under bright field microscope, cells invasived and attached to the transwell membrane were observed and counted, results were statistically analyzed by student test. Results: Selecte five high-power microscopic field randomly, counted the number of adipose derived stem cells migrated to transwell membrane of different cell lines. Results showed that migrated cell number of SACC-LM group was 64.3 ± 7.6, the number of SACC-83 group was 52.3 ± 6.1, both higher than the T293 group (31.8 ± 6.3), and the difference between them was statistically significant (p <0.05). Conclusions: Adipose derived stem cells have obvious chemotaxis to adenoid cystic carcinoma cell culture supernatants, so we can propose that adipose derived stem cells has the possibility and feasibiliy of being used as a targeted therapy vectors for ACC.
Prognostic markers for oropharyngeal cancer after docetaxel, 5-FU, and cisplatin induction chemotherapy followed by concurrent chemoradiotherapy.
Authors: Cho Sang-Hee , Bae Woo Kyun , Shim Hyun-Jeong , Choi Won-young , Hwang Jun-Eul , Choi Yoo-Duk , Lim Sang-Chul , Chung Ik-Joo 
Published: March 2020

e17005 Background: HPV is associated with prognosis of oropharyngeal cancer, and the incidence has been increased in not only western countries, but also Asian. This study aims to assess the prognostic role of HPV expression and clinical factors after induction chemotherapy followed by chemoradiotherapy for locally advanced oropharyngeal cancer in Korean patients. Methods: A retrospective review of 74 patients with known HPV status and treated with the induction chemotherapy of docetaxel, cisplatin and 5-FU followed by chemoradiotherapy was performed. HPV infection was evaluated with in situ hybridization (ISH) for HPV and p16 protein expression. Results: The median age is 65 (range 43-80) years with male 69, female 5. Among them, 36 patients (49%) are current smokers and 17 patients (23%) are heavy drinkers. Nine patients (12%) show HPV positive in ISH and 35 patients (47%) expressed p16 protein. In response analysis, there is an increasing trend of complete response (CR) in p16 positive patients (34.3%) compared with p16 negative patients (17.9%; P=0.055). HPV expression had no significance with CR. Tumor recurrence showed significantly higher in HPV-negative patients (P=0.044) and p16 (P=0.015) than HPV and p16 positive patients, respectively. In survival analysis, even though the median value was not reached until this time, it showed better trend of PFS in p16 positive patients than p16 negative patients (P=0.072). In univariate analysis of HPV status and clinical parameters, the expression of p16 or HPV had no significant association with survival. However, performance status (PS), T staging, tumor response are significant factors associated with PFS. And PS (0 vs. 1-2) showed a strong relation with PFS in multivariate analysis (HR: 0.24, P=0.001) Conclusions: p16 is a prognostic marker for oropharyngeal cancer patients treated with triple induction chemotherapy followed by CRT and it would be a better surrogate marker for HPV infection than HPV ISH. In addition to biomarker, clinical parameter such as PS has been still important factor of treatment outcome in oropharyngeal cancer patients.
Predicitve factors of cisplatin (CDDP) discontinuation in concurrent chemoradiotherapy (CCRT) to locally advanced head and neck cancer patients.
Authors: Nakano Kenji , Sato Yasuyoshi , Sato Yukiko , Toshiyasu Takashi , Asari Takao , Shimbashi Wataru , Sasaki Toru , Fukushima Hirofumi , Yonekawa Hiroyuki , Mitani Hiroki , Oguchi Masahiko , Kawabata Kazuyoshi , Takahashi Shunji 
Published: March 2020

e17006 Background: CCRT is a standard therapy for locally advanced head and neck cancer patients, but some patients have intolerance to high dose density of CDDP. Predictive factors for CDDP discontinuation need to be investigated for making appropriate treatment decisions. Methods: We retrospectively analyzed nonmetastatic head and neck cancer patients treated with CCRT with CDDP (80 mg/m2 per 3 weeks) from November 2005 to April 2012 in our institute. Radiation therapy was performed as three-dimensional radiotherapy or intensity-modified radiotherapy (IMRT). Results: A total of 164 patients received CCRT, of which 89 (54 %) were Stage IV;. Primary sites were as follows; oral cavity 7, oropharynx 52, hypopharynx 53, larynx 14, nasopharynx 30, paranasal sinus/nasal cavity 3, and unknown primary 5. IMRT was performed to 54 (33 %) patients. Median follow-up time was 19 months (range 1-69 months); 1-year overall survival (OS) and progression free survival (PFS) were 90 % and 78 %. Non-Stage IV; and high creatinine clearance (>70 ml/min) were associated with longer OS in Cox proportional hazard model. As for CDDP treatment, 75 (46 %) patients completed 3 cycles of CDDP, 69 (42 %) patients received 2 cycles, and 20 (12 %) patients received only 1 cycle. The main reasons for CDDP discontinuation were infection (24 patients) and renal dysfunction (18 patients). In logistic regression analysis, male sex, younger age (< 61 years) and high body mass index (BMI) (>25) were associated with 3 cycles completion of CDDP statistically significantly (p = .002, odds ratio 6.622; p = .006, odds ratio 2.602; p = .035, odds ratio 2.655, respectively). Conclusions: In CCRT to head and neck cancer patients, infection and renal dysfunction were the main reasons for CDDP discontinuation. Sex, age and BMI could be predictive of CDDP completion/discontinuation.